These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 30528938)

  • 1. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
    Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
    Ward DG; Gordon NS; Boucher RH; Pirrie SJ; Baxter L; Ott S; Silcock L; Whalley CM; Stockton JD; Beggs AD; Griffiths M; Abbotts B; Ijakipour H; Latheef FN; Robinson RA; White AJ; James ND; Zeegers MP; Cheng KK; Bryan RT
    BJU Int; 2019 Sep; 124(3):532-544. PubMed ID: 31077629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
    Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
    Lin SY; Linehan JA; Wilson TG; Hoon DSB
    Eur Urol Focus; 2017 Apr; 3(2-3):265-272. PubMed ID: 28753876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.
    Hayashi Y; Fujita K; Matsuzaki K; Eich ML; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Netto GJ; Nonomura N
    Front Oncol; 2020; 10():755. PubMed ID: 32509577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
    Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
    J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
    Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
    EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
    Ogura R; Ito S; Ueda T; Gabata Y; Sako S; Inoue Y; Yamada T; Konishi H; Fujihara A; Ukimura O
    Sci Rep; 2023 Nov; 13(1):19517. PubMed ID: 37945655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating Telomerase
    Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.
    Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC
    J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
    Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
    Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
    Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
    Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.